When competing for food and resources, bacteria employ elaborate strategies to keep rival cells at bay. Scientists have now identified a pathway that allows disease-causing bacteria to attack other bacterial cells by breaking down their cell wall. Pseudomonas aeruginosa is a type of bacteria readily found in everyday environments. It ...

Microbiologists have uncovered a sneaky trick by the bacterium Pseudomonas aeruginosa to oust rivals. It deploys a toxin delivery machine to breach cell walls of competitors without hurting itself. Its means of attack helps it survive in the outside environment and may even help it cause infection. P. aeruginosa is ...

Microbiologists have uncovered a sneaky trick by the bacterium Pseudomonas aeruginosa to oust rivals. It deploys a toxin delivery machine to breach cell walls of competitors without hurting itself.

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE® (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections. The data were presented at the 34th European ...

Today Intercell AG (VSE: ICLL) announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients. The planned double blind study is powered to show a clinically meaningful and statistically significant reduction in overall ...

VIENNA, Oct. 25 /- Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa , a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very ...

MONMOUTH JUNCTION, N.J., Oct. 21 /-Transave, Inc., today reported positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections.  The results demonstrate significant clinical benefit and complete the company's Phase II ...

Many a holiday is ruined by food poisoning, frequently caused by the bacterium Campylobacter jejuni. Although Campylobacter infections are rarely life-threatening they are extremely debilitating and have been linked with the development of Guillain-Barré syndrome, one of the leading causes of non-trauma-induced paralysis worldwide.

Many a holiday is ruined by food poisoning, frequently caused by the bacterium Campylobacter jejuni . Although Campylobacter infections are rarely life-threatening they are extremely debilitating and have been linked with the development of Guillain-Barr syndrome, one of the leading causes of non-trauma-induced paralysis worldwide. ...

The bacterium Campylobacter jejuni is a major cause of food poisoning in humans. Campylobacter jejuni is well adapted to life in the intestines of animals -- and humans -- so it is surprising that it is able to survive on the surface of meat, which is generally stored in ...

New research reveals Small Colony Variants (SCVs) of P. aeruginosa to be a hallmark of chronic infection in cystic fibrosis (CF) patients. Results, published March 12th in the open-access journal PLoS Pathogens, suggest that SCV-mediated persistence might be a good target for antimicrobial chemotherapy.

New research reveals Small Colony Variants (SCVs) of P. aeruginosa to be a hallmark of chronic infection in cystic fibrosis (CF) patients. Results, published March 12 in the open-access journal PLoS Pathogens, suggest that SCV-mediated persistence might be a good target for antimicrobial chemotherapy.